To provide a high and growing level of income with prospects for long-term capital growth.
Name | % Net Assets |
---|---|
Astrazeneca | 2.0% |
Unilever | 1.9% |
GlaxoSmithKline | 1.9% |
Vodafone Group | 1.9% |
BT Group plc 7.50% 2016 | 1.7% |
BP | 1.7% |
Royal Dutch Shell B | 1.7% |
BT Group | 1.6% |
4¼% Treasury Stock 2032 | 1.6% |
Bear Stearns Co 5.375% MTN 18/10/2013 | 1.5% |
Key | % Net Assets |
---|---|
Astrazeneca | 2.0% |
Unilever | 1.9% |
GlaxoSmithKline | 1.9% |
Vodafone Group | 1.9% |
Other | 92.3% |
Date | 25-Apr-2024 |
---|---|
NAV | 194.76p |
Currency | GBP |
Change | -0.29p |
% | -0.15% |
YTD change | -1.04p |
YTD % | -0.53% |
Fund Inception | 20/06/1974 |
---|---|
Fund Manager | Scott McKenzie / Robert Webb |
TER | 0.83 (15-Apr-2012) |
Minimum Investment | |
---|---|
Initial | £500000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.60% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.14 |
You are here: research